Loading...
The 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention featured data from the first head-to-head comparison of elvitegravir (an investigational once-daily integrase inhibitor that requires pharmacologic boosting) and raltegravir (an FDA-approved twice-daily integrase inhibitor) in treatment-experienced patients [Molina J-M et al. Abstract WELBB05].
The trial, sponsored by the maker of elvitegravir, involved 702 patients with screening viral loads ≥1000 copies/mL and either multiclass drug resistance or ≥6 months of exposure to two or more antiretroviral drug classes. The patients were randomized to receive raltegravir or elvitegravir, plus a fully active ritonavir-boosted protease inhibitor (PI) and a third active agent (enfuvi…